DecisionMap Wealth Management LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

DecisionMap Wealth Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 562 shares of the company’s stock, valued at approximately $434,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its holdings in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $606,000. Carrera Capital Advisors bought a new stake in Eli Lilly and Company in the 3rd quarter valued at about $244,000. Moser Wealth Advisors LLC raised its stake in Eli Lilly and Company by 40.0% in the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock valued at $403,000 after acquiring an additional 130 shares during the period. Finally, Empower Advisory Group LLC raised its stake in Eli Lilly and Company by 4.3% in the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock valued at $123,388,000 after acquiring an additional 5,682 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.2 %

Shares of Eli Lilly and Company stock opened at $822.26 on Thursday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The firm has a market capitalization of $779.64 billion, a price-to-earnings ratio of 70.22, a PEG ratio of 1.40 and a beta of 0.34. The firm’s 50 day simple moving average is $829.78 and its two-hundred day simple moving average is $845.29.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a share buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LLY. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.